One-year experience with latanoprostene bunod ophthalmic solution 0.024% in clinical practice: A retrospective observational study.
<h4>Purpose</h4>We evaluated the IOP-lowering efficacy and safety of latanoprostene bunod (LBN) ophthalmic solution 0.024% (Vyzulta®), the first topical nitric oxide-donating prostaglandin analog (PGA), in clinical practice.<h4>Materials and methods</h4>A retrospective medica...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0307132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|